Clinical trials: Patients With Major Depressive Disorder
Major Depressive Disorder
A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous Medication
The objective of the present study is to evaluate whether vortioxetine (10 or 20 mg/day) is at least as effective as agomelatine (25 to 50 mg/day) in patients with depressive symptoms that showed inadequate response to Serotonin…
- Trial name
- REVIVE (NCT01488071)
- Testing
- Vortioxetine (Lu AA21004), Agomelatine
- Volunteers
- 495 people
- Sponsor
- H. Lundbeck A/S
Amphetamine Abuse, Amphetamine Dependence
A Pilot Study of Citicoline add-on Therapy in Patients With Bipolar Disorder or Major Depressive Disorder and Amphetamine Abuse or Dependence
Bipolar disorder (BD) is a common and severe psychiatric illness. Drug and alcohol abuse are very common in people with BD and other mood disorders and are associated with increased rates of hospitalization, violence towards self…
- Conditions
- Amphetamine Abuse, Amphetamine Dependence, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT00377299
- Testing
- Citicoline
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Adjunct in the Treatment of Depressive Disorder
Study to Evaluate the Adjunctive Effect of CreNeuroS™ CNS Fish Oil Plus Softgels in Patients With Major Depressive Disorder Receiving Escitalopram.
To evaluate the efficacy of adjunctive CreNeuroSTM CNS Fish Oil Plus Softgels in patients with Major Depressive Disorder receiving escitalopram.
- Trial name
- VRL-CT-26-006 (NCT07645807)
- Testing
- 1. Escitalopram (as escitalopram oxalate) tablet 2. CreNeuroSTM CNS Fish Oil Plus Softgels
- Where
- India
- Volunteers
- 80 people
- Sponsor
- Sichuan Credit Pharmaceutical Co., Ltd.
Major Depressive Disorder
Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder
The purpose of this study is to assess the safety and efficacy of Lu AA21004 in participants with major depressive disorder after completion of an 8-week double-blind treatment period in a preceding study (Lu AA21004/CCT-003…
- Trial name
- NCT01395147
- Testing
- Lu AA21004
- Where
- 32 sites in Japan
- Volunteers
- 119 people
- Sponsor
- Takeda
Major Depressive Disorder
Evaluation of Efficacy and Safety of add-on Sarcosine in Patients With Major Depressive Disorder
One-third of the patients with major depressive disorder do not respond to conventional antidepressants that act through the mono-aminergic system.
- Trial name
- NCT04975100
- Testing
- Sarcosine and SSRI
- Where
- India
- Volunteers
- 60 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Depressive Disorder, Major, Major Depressive Disorder (MDD)
Depression Study In Elderly Patients
Major Depressive Disorder (MDD) Study in Elderly Outpatients
- Trial name
- NCT00067444
- Testing
- Paroxetine CR
- Where
- 46 sites in United States
- Volunteers
- 560 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
Study of NSI-189 for Major Depressive Disorder
The study will consist of a screening period and a randomized treatment. Approximately 220 subjects who meet eligibility during the screening period will be randomized to initiate a 12-week, double-blind treatment with NSI-189 80…
- Trial name
- NCT02695472
- Testing
- 80 Milligrams NSI-189, 40 Milligrams NSI-189
- Where
- 13 sites in United States
- Volunteers
- 220 people
- Sponsor
- Neuralstem Inc.
Major Depressive Disorder
Safety Study of F2695 SR in Major Depressive Disorder
The purpose of this study is to evaluate the long- term safety of F2695-SR in the treatment of adults with major depressive disorder.
- Trial name
- LVM-MD-04 (NCT01034267)
- Testing
- F2695 SR
- Where
- 68 sites in United States
- Volunteers
- 828 people
- Sponsor
- Forest Laboratories
Depressive Disorder, Major, Unipolar Depression
Deep Brain Stimulation for Major Depressive Disorder
This study is designed as a prospective, multi-centered, double-blind, randomized, controlled 12-month pivotal study to evaluate the safety and efficacy of the ANS Libra® Deep Brain Stimulation System for patients with major…
- Trial name
- NCT00617162
- Testing
- Deep Brain Stimulation, Libra Deep Brain Stimulation System
- Where
- 13 sites in United States, Canada and 1 more
- Volunteers
- 125 people
- Sponsor
- Abbott Medical Devices
Depression
Reconsolidation-Based Intervention for Traumatic Memories
The goal of this clinical trial is to test the effect and underlying mechanism of reconsolidation-based cognitive reappraisal for traumatic memories in patients with major depression disorder.
- Trial name
- NCT06143800
- Testing
- reactivation, cognitive reappraisal intervention
- Volunteers
- 390 people, healthy volunteers welcome
- Sponsor
- Shenzhen Kangning Hospital
Cannabis Use, Major Depressive Disorder
Extended Effects of Cannabis Abstinence on Clinical Symptoms and Cognition in Depression
The prevalence of major depressive disorder (MDD) is ~5.0%, and rates of co-occurring SUDs in these patients approach 40-50%. Specifically, rates of co-morbid cannabis use disorder (CUD) in patients with MDD are elevated 2-3 fold…
- Conditions
- Cannabis Use, Major Depressive Disorder, Cognitive Impairment
- Trial name
- NCT04935619
- Testing
- Contingency Reinforcement, Non-Contingency Reinforcement
- Where
- Canada
- Volunteers
- 52 people
- Sponsor
- Centre for Addiction and Mental Health
Major Depressive Disorder
Korean Post Marketing Surveillance to Observe Effectiveness and Safety of PRISTIQ
On 6 Feb 2014, Pristiq was approved for the treatment of Major Depressive Disorder(MDD) in Korea. In accordance with the Standards for Re-examination of New Drug, it is required to conduct a PMS for 600 patients by 5 Feb 2020.
- Trial name
- PMS (NCT02548949)
- Where
- 22 sites in South Korea
- Volunteers
- 700 people
- Sponsor
- Pfizer
Major Depressive Disorder
Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression
The purpose of this study is to determine whether GLYX-13 reduces depression score in patients with treatment-resistant depression.
- Trial name
- NCT01234558
- Testing
- GLYX-13
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Major Depressive Disorder
Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients
This is an open-label, parallel-group study to evaluate the safety and efficacy of Ropanicant in participants with moderate to severe Major Depressive Disorder (MDD).
- Trial name
- NCT06126497
- Testing
- Ropanicant
- Where
- 10 sites in United States
- Volunteers
- 41 people
- Sponsor
- Suven Life Sciences Limited
Major Depressive Disorder, Bipolar Disorder
Partnership in Medication Management (PIMM) in Patients With Mood Disorders
Investigators are doing this study to examine if a new personalized education program for patients with mood disorders (depression and bipolar disorders) will help them take their medications as prescribed by doctors.
- Trial name
- PIMM (NCT02285608)
- Testing
- PIMM/SAM
- Where
- Canada
- Volunteers
- 166 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Depression
The Efficacy and Safety of tDCS in Patients With Mild to Moderate Major Depressive Disorder
This study evaluated the effectiveness and safety of improving depressive symptoms by applying tDCS for 6 weeks to patients with mild to moderate depression.
- Trial name
- NCT04720040
- Testing
- Mind STIM
- Where
- South Korea
- Volunteers
- 65 people
- Sponsor
- Ybrain Inc.
Postpartum Depression
Lexapro in the Treatment of Patients With Postpartum Depression
The purpose of this study is to determine if Escitalopram (Lexapro) is effective in the treatment of postpartum depression.
- Trial name
- NCT00277108
- Testing
- Escitalopram (Lexapro)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Rochester
Major Depressive Disorder
Effect of Self-administered tDCS in Patients With MDD
In this randomized, single-blinded clinical trial, 58 patients with major depressive disorder were assigned to active and sham tDCS stimulation groups in a 1:1 ratio, and treatment responses were evaluated biweekly over six weeks.
- Trial name
- NCT04543123
- Testing
- tDCS treatment, Antidepressant Drug(escitalopram)
- Where
- South Korea
- Volunteers
- 58 people
- Sponsor
- Jeong-Ho Chae
Major Depressive Disorder
Efficacy Study of Vortioxetine on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder
Major Depressive Disorder (MDD) is a severe and common psychiatric disorder. Although MDD primarily involves mood disturbances, patients also usually present alterations in cognitive function (attention, memory, executive…
- Trial name
- FOCUS (NCT01422213)
- Testing
- Vortioxetine (Lu AA21004)
- Volunteers
- 598 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
This is a multicenter, randomized, double-blind, placebo-controlled parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders…
- Trial name
- NCT05850689
- Testing
- Lumateperone
- Where
- 69 sites in United States, Bulgaria and 5 more
- Volunteers
- 470 people
- Sponsor
- Intra-Cellular Therapies, Inc.